Loss of p53 exacerbates multiple myeloma phenotype by facilitating the reprogramming of hematopoietic stem/progenitor cells to malignant plasma cells by MAFB

Cell Cycle

Volumn 11, Issue 20, 2012, Pages 3896-3900

  Vicente Dueñas, Carolina ^a,b   González Herrero, Inés ^a,b   Cenador, María Begoña García ^a,b   Criado, Francisco Javier García ^a,b   Sánchez García, Isidro ^a,b  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA IBSAL   (Spain)

Author keywords

Cancer stem cell; Cancer therapy; Cell reprogramming; MAFB; Mouse models; Multiple myeloma; Oncogenes; Stem cells

Indexed keywords

EID: 84868015363     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.22186     Document Type: Article

References (39)

1. Eychène A, Rocques N, Pouponnot C. A new MAFia in cancer. Nat Rev Cancer 2008;8:683-93; PMID:19143053; http://dx.doi.org/10.1038/nrc2460.
2. Kelly LM, Englmeier U, Lafon I, Sieweke MH, Graf T. MafB is an inducer of monocytic differentiation. EMBO J 2000;19:1987-97; PMID:10790365; http://dx.doi.org/10.1093/emboj/19.9.1987. (Pubitemid 30237574)
3. Sieweke MH, Tekotte H, Frampton J, Graf T. MafB is an interaction partner and repressor of Ets-1 that inhibits erythroid differentiation. Cell 1996;85:49-60; PMID:8620536; http://dx.doi.org/10.1016/S0092-8674 (00) 81081-8. (Pubitemid 26116806)
4. Gemelli C, Montanari M, Tenedini E, Zanocco Marani T, Vignudelli T, Siena M, et al. Virally mediated MafB transduction induces the monocyte commitment of human CD34+ hematopoietic stem/progenitor cells. Cell Death Differ 2006;13:1686-96; PMID:16456583; http://dx.doi.org/10.1038/sj.cdd.4401860. (Pubitemid 44390856)
5. Sarrazin S, Mossadegh-Keller N, Fukao T, Aziz A, Mourcin F, Vanhille L, et al. MafB restricts M-CSF-dependent myeloid commitment divisions of hematopoietic stem cells. Cell 2009;138:300-13; PMID:19632180; http://dx.doi.org/10.1016/j. cell.2009.04.057.
6. Nishizawa M, Kataoka K, Vogt PK. MafA has strong cell transforming ability but is a weak transactiva-tor. Oncogene 2003;22:7882-90; PMID:12970735; http://dx.doi.org/10.1038/sj.onc.1206526. (Pubitemid 37175852)
7. Pouponnot C, Sii-Felice K, Hmitou I, Rocques N, Lecoin L, Druillennec S, et al. Cell context reveals a dual role for Maf in oncogenesis. Oncogene 2006;25:1299-310; PMID:16247450; http://dx.doi.org/10.1038/sj.onc.1209171. (Pubitemid 43336458)
8. Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC. Focus on multiple myeloma. Cancer Cell 2004;6:439-44; PMID:15542427; http://dx.doi.org/10.1016/j. ccr.2004.10.020. (Pubitemid 39469979)
9. Tosi P, Gamberi B, Giuliani N. Biology and treatment of multiple myeloma. Biol Blood Marrow Transplant 2006;12(Suppl 1):81-6; PMID:16399590; http://dx.doi.org/10.1016/j.bbmt.2005.09.008. (Pubitemid 43034125)
10. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007;7:585-98; PMID:17646864; http://dx.doi.org/10.1038/nrc2189. (Pubitemid 47106630)
11. Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004;5:191-9; PMID:14998494; http://dx.doi.org/10.1016/S1535-6108 (04) 00019-4. (Pubitemid 38283804)
12. Morito N, Yoh K, Fujioka Y, Nakano T, Shimohata H, Hashimoto Y, et al. Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human. Cancer Res 2006;66:812-9; PMID:16424013; http://dx.doi.org/10.1158/0008-5472. CAN-05-2154. (Pubitemid 43165946)
13. Morito N, Yoh K, Maeda A, Nakano T, Fujita A, Kusakabe M, et al. A novel transgenic mouse model of the human multiple myeloma chromosomal transloca-tion t (14;16) (q32;q23). Cancer Res 2011;71:339-48; PMID:21224354; http://dx.doi.org/10.1158/0008-5472. CAN-10-1057.
14. Vicente-Dueñas C, Romero-Camarero I, González-Herrero I, Alonso-Escudero E, Abollo-Jiménez F, Jiang X, et al. A novel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitors. EMBO J 2012; PMID:22903061; http://dx.doi.org/10. 1038/emboj.2012.227.
15. Vicente-Duenas C, Romero-Camarero I, Garcia-Criado FJ, Cobaleda C, Sanchez-Garcia I. The cellular architecture of multiple myeloma. Cell Cycle 2012; In press.
16. Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009;460:1140-4; PMID:19668186; http://dx.doi.org/10.1038/nature08311.
17. Li H, Collado M, Villasante A, Strati K, Ortega S, Cañamero M, et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 2009;460:1136-9; PMID:19668188; http://dx.doi.org/10.1038/nature08290.
18. Marión RM, Strati K, Li H, Murga M, Blanco R, Ortega S, et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 2009;460:1149-53; PMID:19668189; http://dx.doi.org/10.1038/ nature08287.
19. Krizhanovsky V, Lowe SW. Stem cells: The promises and perils of p53. Nature 2009;460:1085-6; PMID:19713919; http://dx.doi.org/10.1038/4601085a.
20. Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 2009;460:1132-5; PMID:19668191; http://dx.doi.org/10.1038/nature08235.
21. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994;4:1-7; PMID:7922305; http://dx.doi.org/10.1016/S0960-9822 (00) 00002-6.
22. Demchenko YN, Kuehl WM. A critical role for the NFkB pathway in multiple myeloma. Oncotarget 2010;1:59-68; PMID:20890394.
23. Shi L, Wang S, Zangari M, Xu H, Cao TM, Xu C, et al. Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget 2010;1:22-33; PMID:20930946.
24. Rowland BD, Bernards R, Peeper DS. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol 2005;7:1074-82; PMID:16244670; http://dx.doi.org/10.1038/ncb1314.
25. Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008;322:949-53; PMID:18845712; http://dx.doi.org/10.1126/sci-ence.1164270.
26. Chen Y, Shi L, Zhang L, Li R, Liang J, Yu W, et al. The molecular mechanism governing the onco-genic potential of SOX2 in breast cancer. J Biol Chem 2008;283:17969-78; PMID:18456656; http://dx.doi.org/10.1074/jbc. M802917200.
27. Tanaka Y, Era T, Nishikawa S, Kawamata S. Forced expression of Nanog in hematopoietic stem cells results in a gammadeltaT-cell disorder. Blood 2007;110:107-15; PMID:17360937; http://dx.doi.org/10.1182/blood-2006-08-039628. (Pubitemid 47026825)
28. Abollo-Jiménez F, Jiménez R, Cobaleda C. Physiological cellular reprogramming and cancer. Semin Cancer Biol 2010;20:98-106; PMID:20188173; http://dx.doi.org/10.1016/j.semcancer.2010.02.002.
29. Abbas HA, Pant V, Lozano G. The ups and downs of p53 regulation in hematopoietic stem cells. Cell Cycle 2011;10:3257-62; PMID:21957490; http://dx.doi.org/10.4161/cc.10.19.17721.
30. Leonova KI, Shneyder J, Antoch M P, Toshkov IA, Novototskaya LR, Komarov PG, et al. A small molecule inhibitor of p53 stimulates amplification of hematopoietic stem cells but does not promote tumor development in mice. Cell Cycle 2010;9:1434-43; PMID:20404530; http://dx.doi.org/10.4161/cc.9.7.11508.
31. Schoppy DW, Ruzankina Y, Brown EJ. Removing all obstacles: a critical role for p53 in promoting tissue renewal. Cell Cycle 2010;9:1313-9; PMID:20234190; http://dx.doi.org/10.4161/cc.9.7.11194.
32. Menendez S, Camus S, Izpisua Belmonte JC. p53: guardian of reprogramming. Cell Cycle 2010;9:3887-91; PMID:20948296; http://dx.doi.org/10.4161/cc.9.19. 13301.
33. Pérez-Caro M, Cobaleda C, González-Herrero I, Vicente-Dueñas C, Bermejo-Rodríguez C, Sánchez-Beato M, et al. Cancer induction by restriction of oncogene expression to the stem cell compartment. EMBO J 2009;28:8-20; PMID:19037256; http://dx.doi.org/10.1038/ emboj.2008.253.
34. Vicente-Dueñas C, Pérez-Caro M, Abollo-Jiménez F, Cobaleda C, Sánchez-García I. Stem-cell driven cancer: "hands-off" regulation of cancer development. Cell Cycle 2009;8:1314-8; PMID:19279406; http://dx.doi.org/10.4161/cc.8.9.8217.
35. Castellanos A, Vicente-Dueñas C, Campos-Sánchez E, Cruz JJ, García-Criado FJ, García-Cenador MB, et al. Cancer as a reprogramming-like disease: implications in tumor development and treatment. Semin Cancer Biol 2010;20:93-7; PMID:20188174; http://dx.doi.org/10.1016/j. semcancer.2010.02.001.
36. Vicente-Dueñas C, Fontán L, Gonzalez-Herrero I, Romero-Camarero I, Segura V, Aznar MA, et al. Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice. Proc Natl Acad Sci USA 2012;109:10534-9; PMID:22689981; http://dx.doi.org/10.1073/pnas.1204127109.
37. Vicente-Dueñas C, Cobaleda C, Martínez-Climent JA, Sánchez-García I. MALT lymphoma meets stem cells. Cell Cycle 2012;11:2961-2; PMID:22825253; http://dx.doi.org/10.4161/cc.21264.
38. Eminli S, Foudi A, Stadtfeld M, Maherali N, Ahfeldt T, Mostoslavsky G, et al. Differentiation stage determines potential of hematopoietic cells for reprogram-ming into induced pluripotent stem cells. Nat Genet 2009;41:968-76; PMID:19668214; http://dx.doi.org/10.1038/ng.428.
39. Kim JB, Greber B, Araúzo-Bravo MJ, Meyer J, Park KI, Zaehres H, et al. Direct reprogramming of human neural stem cells by OCT4. Nature 2009;461:649-3; PMID:19718018; http://dx.doi.org/10.1038/nature08436.